GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (LSE:AZN) » Definitions » Cyclically Adjusted FCF per Share

AstraZeneca (LSE:AZN) Cyclically Adjusted FCF per Share : £2.24 (As of Mar. 2025)


View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

AstraZeneca's adjusted free cash flow per share for the three months ended in Mar. 2025 was £1.361. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is £2.24 for the trailing ten years ended in Mar. 2025.

During the past 12 months, AstraZeneca's average Cyclically Adjusted FCF Growth Rate was 18.50% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 11.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 3.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -5.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of AstraZeneca was 39.60% per year. The lowest was -15.00% per year. And the median was 3.40% per year.

As of today (2025-05-24), AstraZeneca's current stock price is £104.36. AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was £2.24. AstraZeneca's Cyclically Adjusted Price-to-FCF of today is 46.59.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of AstraZeneca was 73.79. The lowest was 14.59. And the median was 45.70.


AstraZeneca Cyclically Adjusted FCF per Share Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted FCF per Share Chart

AstraZeneca Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.52 1.43 1.80 1.86 2.00

AstraZeneca Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.89 1.97 1.98 2.00 2.24

Competitive Comparison of AstraZeneca's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted Price-to-FCF falls into.


;
;

AstraZeneca Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.361/136.1000*136.1000
=1.361

Current CPI (Mar. 2025) = 136.1000.

AstraZeneca Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.221 100.100 0.300
201509 0.624 100.200 0.848
201512 0.019 100.400 0.026
201603 0.492 100.400 0.667
201606 -0.456 101.000 -0.614
201609 0.267 101.500 0.358
201612 0.835 102.200 1.112
201703 -0.190 102.700 -0.252
201706 -0.050 103.500 -0.066
201709 1.119 104.300 1.460
201712 0.262 105.000 0.340
201803 -0.268 105.100 -0.347
201806 -0.174 105.900 -0.224
201809 0.121 106.600 0.154
201812 1.132 107.100 1.439
201903 -0.687 107.000 -0.874
201906 -0.058 107.900 -0.073
201909 0.469 108.400 0.589
201912 0.575 108.500 0.721
202003 -0.146 108.600 -0.183
202006 0.038 108.800 0.048
202009 0.657 109.200 0.819
202012 0.708 109.400 0.881
202103 0.801 109.700 0.994
202106 0.292 111.400 0.357
202109 0.515 112.400 0.624
202112 0.337 114.700 0.400
202203 1.395 116.500 1.630
202206 0.367 120.500 0.415
202209 1.030 122.300 1.146
202212 0.970 125.300 1.054
202303 0.878 126.800 0.942
202306 0.627 129.400 0.659
202309 1.158 130.100 1.211
202312 0.726 130.500 0.757
202403 0.444 131.600 0.459
202406 1.218 133.000 1.246
202409 0.980 133.500 0.999
202412 0.988 135.100 0.995
202503 1.361 136.100 1.361

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


AstraZeneca  (LSE:AZN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

AstraZeneca's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=104.36/2.24
=46.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of AstraZeneca was 73.79. The lowest was 14.59. And the median was 45.70.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


AstraZeneca Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca Business Description

Industry
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.